2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/27/17Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017
PHOENIX, March 27, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors. “We are excited that Saeed, a 20-year veteran of the life sciences industry, has chosen to bring his immense depth of sales and marketing, managed care, and commercial operations experience to In... 
Printer Friendly Version
03/23/17DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
PHOENIX, March 23, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.  On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros. Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical O... 
Printer Friendly Version
03/15/17Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results
-- Fourth Quarter 2016 Net Sales Estimated at $54 million -- PHOENIX, March 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the Company will delay the release of its financial results for the fourth quarter and full year 2016.  The Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorde... 
Printer Friendly Version
03/02/17Insys Therapeutics to Report Fourth Quarter and Full Year 2016 Results
PHOENIX, March 02, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter and full year 2016 on Thursday, March 16, 2017, before the U.S. financial markets open. Following the release of the financial results, Dr. Santosh Vetticaden, Interim CEO, and Chief Medical Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Da... 
Printer Friendly Version
02/15/17Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study
CHANDLER, Ariz., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study.  The long-term safety study permitted subjects who had completed the initial safety and pharmacokinetic (... 
Printer Friendly Version
02/14/17Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference
PHOENIX, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference as follows: Date:   Thursday, February 23, 2017 Time:   1:35 p.m. Eastern Standard Time Location:   The New ... 
Printer Friendly Version
01/09/17Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board
PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive Officer (“CEO”) and Chairman of the Company’s Board of Directors (“Board”) will retire as President and CEO and Chairman effective January 9, 2017.  Dr. Kapoor will remain a member of the Board and will Chair the newly formed Science and Research and Development Committee of the Board.  In connection ... 
Printer Friendly Version
01/04/17Insys Therapeutics, Inc. to Present at J.P. Morgan 35th Annual Healthcare Conference
PHOENIX, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, and Darryl Baker, Chief Financial Officer, will present at the J.P. Morgan 35th Annual Healthcare Conference as follows: Date:   Monday, January 9, 2017   Time:   4:00 p.m. Pacific Standard Time   Location:   We... 
Printer Friendly Version